Older people who regularly drink green tea have fewer brain lesions are characteristic of dementia than those who do not ...

Tabelecleucel, an allogeneic, EBV-specific T-cell immunotherapy, works by targeting and eliminating EBV-infected cells.

Atara stock plunges 41% upon the FDA issuance of a CRL against its BLA for Ebvallo to treat EBV+ PTLD. The company is also facing a severe cash crunch.

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/17.DwxO7Jta.js ...

Information on tumor mutational status was limited before the development of NGS because traditional Sanger sequencing and ...

Individual carriers of a premutation (PM) allele with 55–200 CGG repeats are typically unmethylated and can present with clinical features defined as FMR1-associated conditions. Methods Blood samples ...

The FDA has issued a complete response letter to the biologics license application seeking the approval of tabelecleucel for ...

Research led by the Kanazawa University Graduate School of Medical Sciences has reported a significant connection between ...

As per NPJ - Science of Food, participants who drank 600 ml of green tea as compared to a consumption level of 200 ml had 3% less brain damage.

A new study finds that dementia cases will increase at a much higher rate than expected, with lifetime risk rising to 42 ...

U.S. dementia cases were projected to reach 1 million annually by 2060, doubling from 514,000 cases in 2020. Dementia cases ...

Shares of Atara Biotherapeutics, Inc. (NASDAQ:ATRA) tumbled 51% after the company disclosed receiving a Complete Response ...